Loading...

Neil Mehta, MD

Title(s)Associate Professor, Medicine
SchoolSchool of Medicine
Phone415-502-2569
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoM.D.2006 Medicine

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Lee E, Sarkar M, Dodge J, Kohi M, Mehta N. Shorter Height is Associated with Lower Probability of Liver Transplantation in Patients with Hepatocellular Carcinoma. Transplantation. 2019 Sep 30. PMID: 31577670.
      View in: PubMed
    2. Gutin L, Yao F, Dodge JL, Grab J, Mehta N. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance. JAMA Netw Open. 2019 Aug 02; 2(8):e1910326. PMID: 31469395.
      View in: PubMed
    3. Acar YA, Mehta N, Rich MA, Yilmaz BK, Careskey M, Generoso J, Fidler R, Hirsch J. Using Standardized Checklists Increase the Completion Rate of Critical Actions in an Evacuation from the Operating Room: A Randomized Controlled Simulation Study. Prehosp Disaster Med. 2019 Aug; 34(4):393-400. PMID: 31389323.
      View in: PubMed
    4. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Ioannou GN, Huang A, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Kagan S, Gopal P, Wong R, Parikh ND, Murphy CC. Direct-Acting Antiviral Therapy for HCV Infection is Associated with Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology. 2019 Jul 30. PMID: 31374215.
      View in: PubMed
    5. Rich NE, Yang JD, Perumalswami PV, Alkhouri N, Jackson W, Parikh ND, Mehta N, Salgia R, Duarte-Rojo A, Kulik L, Rakoski M, Said A, Oloruntoba O, Ioannou GN, Hoteit MA, Moon AM, Rangnekar AS, Eswaran SL, Zheng E, Jou JH, Hanje J, Pillai A, Hernaez R, Wong R, Scaglione S, Samant H, Kapuria D, Chandna S, Rosenblatt R, Ajmera V, Frenette C, Satapathy SK, Mantry P, Jalal P, John BV, Fix OK, Leise M, Lindenmeyer CC, Flores A, Patel N, Jiang ZG, Latt N, Dhanasekaran R, Odewole M, Kagan S, Marrero JA, Singal AG. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients with Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2019 Jul 26. PMID: 31357028.
      View in: PubMed
    6. Mehta N, Dodge JL, Grab JD, Yao FY. National Experience on Down-staging of Hepatocellular Carcinoma before Liver Transplant: Influence of Tumor Burden, AFP, and Wait Time. Hepatology. 2019 Jul 25. PMID: 31344273.
      View in: PubMed
    7. Mehta N, Dodge JL, Yao FY. Reply (to LTE HEP-19-0464). Hepatology. 2019 May 16. PMID: 31095762.
      View in: PubMed
    8. Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation. Am J Transplant. 2019 Mar 12. PMID: 30861298.
      View in: PubMed
    9. Subramanian A, Connor DM, Berger G, Lessing JN, Mehta N, Manesh R, Kohlwes J. A Curriculum for Diagnostic Reasoning: JGIM's Exercises in Clinical Reasoning. J Gen Intern Med. 2019 Mar; 34(3):344-345. PMID: 30334181.
      View in: PubMed
    10. Mehta N, Yao FY. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma? Clin Liver Dis (Hoboken). 2019 Jan; 13(1):20-25. PMID: 31168361.
      View in: PubMed
    11. Sinha J, Mehta N, Dodge JL, Poltavskiy E, Roberts J, Yao F. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol. Hepatology. 2019 Feb 19. PMID: 30779440.
      View in: PubMed
    12. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology. 2019 Mar; 69(3):1193-1205. PMID: 30548884.
      View in: PubMed
    13. Lee DD, Samoylova M, Mehta N, Musto KR, Roberts JP, Yao FY, Harnois DM. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Liver Transpl. 2019 Feb; 25(2):228-241. PMID: 30198150.
      View in: PubMed
    14. Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl. 2019 Feb; 25(2):207-216. PMID: 30246323.
      View in: PubMed
    15. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology. 2019 Jan 18. PMID: 30660729.
      View in: PubMed
    16. Mehta N, Monto A, Yao FY. Screening for Hepatocellular Carcinoma to Improve Cancer-Related Mortality: Looking Behind When We Should Be Looking Ahead. Gastroenterology. 2019 03; 156(4):1215-1217. PMID: 30543796.
      View in: PubMed
    17. Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, Muiesan P, Mazzaferro V, Sapisochin G. Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation. HPB (Oxford). 2018 Oct 31. PMID: 30391218.
      View in: PubMed
    18. Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation. Liver Transpl. 2018 10; 24(10):1346-1356. PMID: 30067889.
      View in: PubMed
    19. Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma. Liver Transpl. 2018 09; 24(9):1171-1177. PMID: 29781162.
      View in: PubMed
    20. Roberts DE, Kakar S, Mehta N, Gill RM. A Point-based Histologic Scoring System for Hepatocellular Carcinoma Can Stratify Risk of Posttransplant Tumor Recurrence. Am J Surg Pathol. 2018 07; 42(7):855-865. PMID: 29649017.
      View in: PubMed
    21. Lewin SM, Kallianos K, Nevah MI, Zhao S, Fix OK, Brooks GC, De Marco T, Qasim AN, Ordovas KG, Mehta N. Cardiac MRI T2* in Liver Transplant Candidates: Application and Performance of a Novel Imaging Technique to Identify Patients at Risk for Poor Posttransplant Cardiac Outcomes. Transplant Direct. 2018 Jul; 4(7):e363. PMID: 30046653.
      View in: PubMed
    22. Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology. 2018 08; 68(2):449-461. PMID: 29476694.
      View in: PubMed
    23. Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma. Transplantation. 2018 05; 102(5):816-822. PMID: 29505494.
      View in: PubMed
    24. Lee BP, Mehta N, Platt L, Gurakar A, Rice JP, Lucey MR, Im GY, Therapondos G, Han H, Victor DW, Fix OK, Dinges L, Dronamraju D, Hsu C, Voigt MD, Rinella ME, Maddur H, Eswaran S, Hause J, Foley D, Ghobrial RM, Dodge JL, Li Z, Terrault NA. Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. Gastroenterology. 2018 08; 155(2):422-430.e1. PMID: 29655837.
      View in: PubMed
    25. Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, Grant DR, Yao F, Sapisochin G. Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma. Transplantation. 2018 04; 102(4):640-647. PMID: 29319620.
      View in: PubMed
    26. Mehta N, Yao FY. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)? Liver Transpl. 2018 03; 24(3):327-329. PMID: 29351366.
      View in: PubMed
    27. Azeem N, Ajmera V, Hameed B, Mehta N. Hilar cholangiocarcinoma associated with immunoglobulin G4-positive plasma cells and elevated serum immunoglobulin G4 levels. Hepatol Commun. 2018 04; 2(4):349-353. PMID: 29619414.
      View in: PubMed
    28. Mehta NJ, Latoures R, Stechert MM, Fidler RL, Hirsch J. Interventions to improve the mechanical ventilation fidelity of the Laerdal SimMan® 3G simulation mannequin. Can J Anaesth. 2018 05; 65(5):600-602. PMID: 29243162.
      View in: PubMed
    29. Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018 05; 18(5):1206-1213. PMID: 29068145.
      View in: PubMed
    30. Mehta N, Yao FY. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma. Liver Transpl. 2017 12; 23(12):1596-1600. PMID: 29024442.
      View in: PubMed
    31. Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol. 2018 06; 16(6):955-964. PMID: 29175528.
      View in: PubMed
    32. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form. Clin Transplant. 2017 Nov; 31(11). PMID: 28881064.
      View in: PubMed
    33. Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation. 2017 09; 101(9):2071-2078. PMID: 28353492.
      View in: PubMed
    34. Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma. Liver Transpl. 2017 08; 23(8):1015-1022. PMID: 28340509.
      View in: PubMed
    35. Sabatino JJ, Mehta NJ, Kakar S, Zamvil SS, Cree BAC. Acute liver injury in a Glatopa-treated patient with MS. Neurol Neuroimmunol Neuroinflamm. 2017 Jul; 4(4):e368. PMID: 28626784.
      View in: PubMed
    36. Salazar J, Saxena V, Kahn JG, Roberts JP, Mehta N, Volk M, Lai JC. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma. Transplantation. 2017 05; 101(5):1001-1008. PMID: 27926593.
      View in: PubMed
    37. Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017 Apr 01; 3(4):493-500. PMID: 27838698.
      View in: PubMed
    38. Mehta NJ, Celik AD, Peters MG. Screening for hepatocellular carcinoma: What is missing? Hepatol Commun. 2017 02; 1(1):18-22. PMID: 29404430.
      View in: PubMed
    39. Mehta N, Yao FY. Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When… and Y(90)? Gastroenterology. 2016 12; 151(6):1062-1065. PMID: 27983951.
      View in: PubMed
    40. Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016 10; 64(4):1178-88. PMID: 27481548.
      View in: PubMed
    41. Mehta N, Yao FY. Reply. Liver Transpl. 2016 08; 22(8):1164-5. PMID: 27097078.
      View in: PubMed
    42. Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N.  Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant. Ann Hepatol. 2016 Jul-Aug; 15(4):545-9. PMID: 27236153.
      View in: PubMed
    43. Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N. Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant. Ann Hepatol. 2016 Jul - Aug; 15(4):545-549. PMID: 31227113.
      View in: PubMed
    44. Mehta N, Roberts JP, Yao FY. Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story? Liver Transpl. 2016 05; 22(5):582-4. PMID: 26951991.
      View in: PubMed
    45. Lê-Scherban F, Albrecht SS, Bertoni A, Kandula N, Mehta N, Diez Roux AV. Immigrant status and cardiovascular risk over time: results from the Multi-Ethnic Study of Atherosclerosis. Ann Epidemiol. 2016 06; 26(6):429-435.e1. PMID: 27221804.
      View in: PubMed
    46. Mehta N, Yao FY. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan. Curr Opin Organ Transplant. 2016 Apr; 21(2):91-8. PMID: 26807513.
      View in: PubMed
    47. Mehta N, Yao FY. Nucleos(t)ide analogs reduce the risk of hepatitis B-associated hepatocellular carcinoma: A can't miss proposition? Hepatology. 2016 May; 63(5):1415-7. PMID: 26679367.
      View in: PubMed
    48. Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl. 2016 Feb; 22(2):178-87. PMID: 26479422.
      View in: PubMed
    49. Mehta N, Heimbach J, Hirose R, Roberts JP, Yao FY. Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy? Gastroenterology. 2016 Feb; 150(2):533-4. PMID: 26718172.
      View in: PubMed
    50. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK, Roberts JP. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015 Jun; 61(6):1968-77. PMID: 25689978.
      View in: PubMed
    51. Samoylova ML, Dodge JL, Mehta N, Yao FY, Roberts JP. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm. Clin Transplant. 2015 Jan; 29(1):52-9. PMID: 25366656.
      View in: PubMed
    52. Goel A, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, Terrault N. Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. Liver Transpl. 2014 Oct; 20(10):1221-8. PMID: 25045002.
      View in: PubMed
    53. Yao FY, Hameed B, Mehta N, Roberts JP. Response to letter to the editors. Liver Transpl. 2014 Oct; 20(10):1285. PMID: 25155484.
      View in: PubMed
    54. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014 Aug; 20(8):945-51. PMID: 24797281.
      View in: PubMed
    55. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list. Liver Transpl. 2014 May; 20(5):627-8. PMID: 24493311.
      View in: PubMed
    56. Srinivasan M, Mehta N. BMJ endgames: a new web-based BMJ/JGIM collaboration. J Gen Intern Med. 2014 Mar; 29(3):423-4. PMID: 24395105.
      View in: PubMed
    57. Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl. 2013 Dec; 19(12):1343-53. PMID: 24285611.
      View in: PubMed
    58. Mendelsohn BA, Mehta N, Hameed B, Pekmezci M, Packman S, Ralph J. Adult-Onset Fatal Neurohepatopathy in a Woman Caused by MPV17 Mutation. JIMD Rep. 2014; 13:37-41. PMID: 24190800.
      View in: PubMed
    59. Mehta N, Yao FY. Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation. Liver Transpl. 2013 Oct; 19(10):1055-8. PMID: 23959652.
      View in: PubMed
    60. Yao F, Mehta N. Reply: To PMID 23333661. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1674. PMID: 24035772.
      View in: PubMed
    61. Mehta N, Hirose R. Immunosuppression: Conventions and controversies. Clin Liver Dis (Hoboken). 2013 Aug; 2(4):188-191. PMID: 30992859.
      View in: PubMed
    62. Mehta N, Fidelman N, Sarkar M, Yao FY. Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013 May; 11(5):572-8. PMID: 23333661.
      View in: PubMed